Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) surged about 33% to $7.68 in premarket trading Monday after the company announced late Friday that the U.S. Food and Drug Administration had approved its drug Bysanti, sparking strong after-hours gains.
The sharp move shifted investor focus to whether the rally can hold through regular trading, particularly after the stock had fallen 5.5% during Friday’s session before the approval news was released.
Market participants are now closely watching Vanda’s next steps following the regulatory decision, as the company transitions from awaiting clinical milestones to preparing for commercialization. Key questions include how quickly prescriptions ramp up after launch and whether the price jump reflects sustained investor confidence or short-covering activity.
Vanda said Friday that its antipsychotic treatment Bysanti received FDA approval for the treatment of schizophrenia and acute bipolar I disorder. The therapy targets dopamine and serotonin receptors, which play central roles in regulating mood and behavior.
Vanda Chief Executive Officer Mihael H. Polymeropoulos described the approval of BYSANTI as “a significant step forward,” adding that it provides a “reliable new treatment” supported by the company’s clinical research. The company plans to begin commercial rollout in the third quarter of 2026.
Bysanti, also known as milsaperidone, is bioequivalent to iloperidone across the full therapeutic dosing range, according to Vanda. The company already markets iloperidone under the Fanapt brand, a connection that could simplify commercialization but may also raise questions about product differentiation.
Ahead of the decision, Jefferies analyst Andrew Tsai noted that Bysanti is “essentially more or less the same drug” as Fanapt, with similar efficacy and safety characteristics. He also highlighted the possibility that generic versions of Fanapt could enter the market as early as late 2027 or 2028, potentially pressuring pricing and demand.